The stock of Century Therapeutics Inc (IPSC) has seen a 8.56% increase in the past week, with a -2.16% drop in the past month, and a -40.36% decrease in the past quarter. The volatility ratio for the week is 8.19%, and the volatility levels for the past 30 days are at 11.35% for IPSC. The simple moving average for the past 20 days is 12.25% for IPSC’s stock, with a -57.30% simple moving average for the past 200 days.
Is It Worth Investing in Century Therapeutics Inc (NASDAQ: IPSC) Right Now?
Moreover, the 36-month beta value for IPSC is 1.71. Analysts have varying opinions on the stock, with 3 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for IPSC is 38.84M and currently, short sellers hold a 8.07% of that float. On April 24, 2025, IPSC’s average trading volume was 531.57K shares.
IPSC) stock’s latest price update
Century Therapeutics Inc (NASDAQ: IPSC)’s stock price has plunge by 0.52relation to previous closing price of 0.54. Nevertheless, the company has seen a 8.56% surge in its stock price over the last five trading sessions. zacks.com reported 2025-03-25 that Century Therapeutics (IPSC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Analysts’ Opinion of IPSC
Many brokerage firms have already submitted their reports for IPSC stocks, with Rodman & Renshaw repeating the rating for IPSC by listing it as a “Buy.” The predicted price for IPSC in the upcoming period, according to Rodman & Renshaw is $6 based on the research report published on August 08, 2024 of the previous year 2024.
JP Morgan, on the other hand, stated in their research note that they expect to see IPSC reach a price target of $5, previously predicting the price at $28. The rating they have provided for IPSC stocks is “Neutral” according to the report published on August 28th, 2023.
Chardan Capital Markets gave a rating of “Buy” to IPSC, setting the target price at $19 in the report published on December 27th of the previous year.
IPSC Trading at -6.78% from the 50-Day Moving Average
After a stumble in the market that brought IPSC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -85.33% of loss for the given period.
Volatility was left at 11.35%, however, over the last 30 days, the volatility rate increased by 8.19%, as shares sank -2.88% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -26.10% lower at present.
During the last 5 trading sessions, IPSC rose by +8.00%, which changed the moving average for the period of 200-days by -76.52% in comparison to the 20-day moving average, which settled at $0.4834. In addition, Century Therapeutics Inc saw -46.26% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IPSC starting from Pfeiffenberger Brent, who sale 2,235 shares at the price of $0.61 back on Mar 10 ’25. After this action, Pfeiffenberger Brent now owns 1,190,310 shares of Century Therapeutics Inc, valued at $1,375 using the latest closing price.
Russotti Gregory, the of Century Therapeutics Inc, sale 2,360 shares at $0.61 during a trade that took place back on Mar 10 ’25, which means that Russotti Gregory is holding 272,573 shares at $1,451 based on the most recent closing price.
Stock Fundamentals for IPSC
Current profitability levels for the company are sitting at:
- -21.08 for the present operating margin
- -0.52 for the gross margin
The net margin for Century Therapeutics Inc stands at -19.21. The total capital return value is set at -0.62. Equity return is now at value -73.14, with -35.46 for asset returns.
Based on Century Therapeutics Inc (IPSC), the company’s capital structure generated 0.25 points at debt to capital in total, while cash flow to debt ratio is standing at -2.05.
Currently, EBITDA for the company is -111.47 million with net debt to EBITDA at 0.04. When we switch over and look at the enterprise to sales, we see a ratio of 6.35. The receivables turnover for the company is 4.34for trailing twelve months and the total asset turnover is 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.50.
Conclusion
To wrap up, the performance of Century Therapeutics Inc (IPSC) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
